October 10, 2024 – Policy & Medicine
6 days ago · Legal, Regulatory, and Compliance Issues. Owners of a wholesale drug distributor were recently indicted in the Southern District of Florida for alleged engagement in a…
DaVita Reaches $34 Million False Claims Act Settlement
Sep 12, 2024 · DaVita has agreed to pay more than $34 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce referrals to DaVita Rx, a former subsidiary that provided pharmacy services for dialysis patients, and by paying kickbacks to nephrologists and vascular access physicians to induce …
FDA Social Media Guidance: Presenting Risks and Benefits With …
Jun 18, 2014 · The Food and Drug Administration (FDA) released two new guidances for drug and device companies looking to communicate online through social media. In the first of its new guidances, entitled "Internet/Social Media Platforms with Character Spac
Guardant Health Reaches False Claims Act Settlement Over Hiring ...
Sep 13, 2024 · Guardant Health, Inc., a precision oncology company in California, reached a settlement with the United States Department of Justice (DOJ) to resolve allegations that it knowingly violated the False Claims Act and regulations of the Defense Health Agency (DHA). Guardant will pay $913,932.93 to settle the False Claims Act allegations and an additional $31,082 in an administrative settlement ...
Institute of Medicine Report – The Future of Nursing: Leading …
Feb 17, 2011 · As the current debate surrounding the Affordable Care Act (ACA) continues in Congress, a number of strengths and weaknesses of the legislation are being emphasized. One specific issue is how the American health care system will treat an additional 32
Rare Disease Community Pushes Back Against Inflation Reduction …
Aug 16, 2024 · Bloomberg recently wrote about a push by the rare disease community for changes in the Inflation Reduction Act’s drug price-setting rules. The article notes that some pharmaceutical companies have announced that they plan to stop or shift their research into rare disease or small-molecule drugs out of fear that they would not recoup their costs under the Medicare Drug Price Negotiation Program.
Policy & Medicine – Legal, Regulatory, and Compliance Issues
Legal, Regulatory, and Compliance Issues. This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key independent symposiums by Clinical Care Options attracting attention from hepatology and gastroenterology professionals worldwide.
CMS Releases Report on 2022 Quality Payment Program Data
Aug 12, 2024 · Recently, the Centers for Medicare and Medicaid Services (CMS) released a report that provides insight into clinicians’ performance in the Quality Payment Program (QPP) in 2022. The QPP has two tracks, the Merit-based Incentive Payment System (MIPS) or the Advanced Alternative Payment Model (Advanced APM).
HHS OIG Issues Report on Two Midnight Rule in Medicare
Sep 10, 2024 · OIG’s first explanation for why Medicare is overpaying for inpatient hospital services is that there is ineffective information gathering. Some inpatient hospital stays lasting less than two-midnights might still qualify for Medicare Part A reimbursement when patients received services that are on the inpatient only (IPO) procedures list.
October 8, 2024 – Policy & Medicine
Oct 8, 2024 · Legal, Regulatory, and Compliance Issues. In a recent global compliance presentation at the Informaconnect Transparency, Aggregate Spend and HCP Engagement, Elon Shelf,…